Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Wang Zongsong
- Phone Number: 18660190175
- Email: wzsong3@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Over 18 years old;
- Patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, minimal change nephropathy confirmed by renal biopsy;
- Had not received hormone and/or immunosuppressive therapy before renal biopsy;
- Complete clinical data, all signed the "Admission Certificate of Qianfoshan Hospital of Shandong Province", and agreed to use relevant medical information, biological specimen examination and examination results for scientific research.
Exclusion Criteria:
- There are factors causing secondary membranous nephropathy, such as immune diseases (systemic lupus erythematosus), tumors/infections (viral hepatitis), drugs or poisons, etc.;
- Severe infection: fever, cough and expectoration, sore throat, abdominal pain, diarrhea, carbuncle and furuncle and other clinical manifestations of skin and soft tissue infection, blood routine white blood cell count beyond the normal range (10×109/L);
- Severe cardiovascular disease: including chronic heart failure grade 3 or above and various arrhythmias;
- Infectious diseases: active hepatitis, AIDS, syphilis, etc. ;
- Tumor evidence: it has been found that there is a certain tumor or clinical manifestations, tumor markers, etc., suggesting the possibility of tumor.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
diabetic nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy.
The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius.
The images were divided into a training set and a test set at a fixed ratio.
The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test.
The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model.
The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
|
Microscopic hyperspectral imaging system
|
|
minimal change nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy.
The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius.
The images were divided into a training set and a test set at a fixed ratio.
The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test.
The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model.
The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
|
Microscopic hyperspectral imaging system
|
|
IgA nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy.
The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius.
The images were divided into a training set and a test set at a fixed ratio.
The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test.
The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model.
The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
|
Microscopic hyperspectral imaging system
|
|
idiopathic membranous nephropathy
Urine samples were collected from patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy and minimal change nephropathy.
The samples were centrifuged and frozen in a refrigerator at -80 degrees Celsius.
The images were divided into a training set and a test set at a fixed ratio.
The digital images were input into classification models such as one-dimensional convolutional neural network to learn and test.
The training set was used for the training and parameter iteration of the artificial intelligence non-invasive fluid diagnosis model, and the test set was used for the recognition and interpretation of the model.
The confusion matrix, accuracy and ROC curve were calculated through the interpretation results to evaluate the performance of the model.
|
Microscopic hyperspectral imaging system
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microhyperspectral image of urine specimen
Time Frame: 2023.4-2023.10
|
Microhyperspectral images of urine samples from patients with four different glomerular diseases before treatment
|
2023.4-2023.10
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- liquid biopsy-glomerulopathy
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.